GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- A3752 Reparixin1 CitationTarget: CXCRSummary: Inhibitor of CXCL8 receptor and CXCR1/CXCR2 activation
- A3753 Reparixin L-lysine salt1 CitationTarget: CXCRSummary: CXCR1/CXCR2 inhibitor
- A3766 Rimonabant hydrochlorideSummary: CB1 receptor inverse agonist
- A3776 RotigotineSummary: Agonist of dopamine D2/D3 receptor
- A3777 Rotigotine hydrochlorideSummary: Agonist of dopamine D2/D3 receptor
- A3779 RS 5043931 CitationSummary: CCR2 chemokine receptor antagonist
- A3789 Salmeterol xinafoateSummary: β2-adrenergic receptor agonist
- A3795 SB-222200Summary: Human NK-3 receptor antagonist
- A3798 SB-408124 HydrochlorideSummary: OX1 receptor antagonist,selective and non-peptide
- A3800 SB-674042Summary: OX1 selective antagonist